Abstract: Cell therapy is getting a growing interest in a wide range of indications in human. In many cases, a substantial part of the therapeutic effects relies on cell-secreted factors and the extracellular vesicles (EV) are proposed as a cell-free surrogate for cell therapy. Currently, during the EV production phase, human cells are placed in serum-free media to produce EV, with limited cell survival. Here, the inventors describe a new procedure for GMP-compatible human cells-derived EV wherein Human Platelet Lysate (HPL) is produced from which the EV are removed by tangential-flow-filtration resulting in an EV-depleted HPL. Said EV-depleted HPL may be then uses as a culture medium for the production of EV by cells of interest.

Abstract: The present invention relates to the use of gingival fibroblast-derived products to reduce hair loss and promote hair growth. Specifically, the invention relates to a product derived from gingival fibroblasts to be used in the treatment or prevention of alopecia, as well as in the promotion of natural hair growth and/or in the control of natural hair loss.

Abstract: The present invention relates to the use of gingival fibroblast-derived products to reduce hair loss and promote hair growth. Specifically, the invention relates to a product derived from gingival fibroblasts to be used in the treatment or prevention of alopecia, as well as in the promotion of natural hair growth and/or in the control of natural hair loss.

Abstract: The present invention relates to a method for preventing or treating cancer in an individual comprising administering the individual with a prophylactically or therapeutically effective quantity of a gingival fibroblast-derived product.

Abstract: The present invention relates to a culture support for cultivating hematopoietic stem cells (HSCs) and/or hematopoietic progenitors (HPs), comprising a calcium biomaterial, osteoclasts, endothelial cells and mesenchymatous stem cells (MSCs) and/or osteoblasts and/or adipocytes. The present invention also relates to a method for preparing such a culture support, and an in vitro HSC and/or HP cultivation method. The use of such a culture support for studying cellular mechanisms involved in hematopoiesis and/or differentiation of HSC/HPs and/or for studying the efficacy and/or the toxicity of a medicament candidate is also described.

Abstract: The present invention relates to the use of gingival fibroblasts-derived products to reduce hair loss and promote hair growth. Specifically, the invention relates to a product derived from gingival fibroblasts to be used in the treatment or prevention of alopecia, as well as in the promotion of natural hair growth and/or in the control of natural hair loss.

Abstract: The present invention relates to a culture support for cultivating hematopoietic stem cells (HSCs) and/or hematopoietic progenitors (HPs), comprising a calcium biomaterial, osteoclasts, endothelial cells and mesenchymatous stem cells (MSCs) and/or osteoblasts and/or adipocytes. The present invention also relates to a method for preparing such a culture support, and an in vitro HSC and/or HP cultivation method. The use of such a culture support for studying cellular mechanisms involved in hematopoiesis and/or differentiation of HSC/HPs and/or for studying the efficacy and/or the toxicity of a medicament candidate is also described.

Abstract: The present invention relates to a method for preventing or treating cancer in an individual comprising administering the individual with a prophylactically or therapeutically effective quantity of a gingival fibroblast-derived product.